Reduction in the risk of human breast cancer by selecti inhibitors

BMC Cancer

6, 27

DOI: 10.1186/1471-2407-6-27

Citation Report

#	Article	IF	Citations
1	Prevention of breast cancer: current state of the science and future opportunities. Expert Opinion on Investigational Drugs, 2006, 15, 1583-1600.	4.1	19
2	Microscopic Modes and Free Energies of 3-Phosphoinositide-Dependent Kinase-1 (PDK1) Binding with Celecoxib and Other Inhibitors. Journal of Physical Chemistry B, 2006, 110, 26365-26374.	2.6	29
3	The Effect of a Cyclooxygenase-2 Inhibitor on Proliferating Activity in Breast Cancer: First Results. Breast Care, 2006, 1, 320-323.	1.4	0
4	Celecoxib decreases prostaglandin E2concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer. BMC Cancer, 2006, 6, 248.	2.6	12
5	Chemoprevention of Breast Cancer. Women's Health, 2006, 2, 733-741.	1.5	11
6	Chemoprevention of Breast Cancer. Women's Health, 2006, 2, 853-861.	1.5	1
7	Peroxisome profilerator-activated receptorÂ2 Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis, 2006, 28, 427-434.	2.8	74
8	Nonsteroidal Antiinflammatory Drugs and Breast Cancer Risk: The Multiethnic Cohort. American Journal of Epidemiology, 2007, 166, 1150-1158.	3.4	65
9	Molecular Pathways for Cancer Angioprevention: Fig. 1.. Clinical Cancer Research, 2007, 13, 4320-4325.	7.0	48
10	Cancer Chemoprevention by Cyclooxygenase 2 (COX-2) Blockade. Sub-Cellular Biochemistry, 2007, 42, 193-212.	2.4	79
11	Nonsteroidal Antiinflammatory Drug Use and Breast Cancer Risk: Subgroup Findings. American Journal of Epidemiology, 2007, 166, 709-716.	3.4	50
12	Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials. Oncologist, 2007, 12, 375-389.	3.7	32
13	Cyclooxygenase-2 (COX-2) and the Inflammogenesis of Cancer. Sub-Cellular Biochemistry, 2007, 42, 93-126.	2.4	152
14	Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Research, 2007, 9, 210.	5.0	261
15	Interaction between Comorbidity and Cancer. Cancer Control, 2007, 14, 13-22.	1.8	180
16	Reduced Risk of Human Lung Cancer by Selective Cyclooxygenase 2 (Cox-2) Blockade: Results of a Case Control Study. International Journal of Biological Sciences, 2007, 3, 328-334.	6.4	79
17	Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. International Journal of Cancer, 2007, 121, 211-215.	5.1	43
18	Inhibition of breast tumor growth and angiogenesis by a medicinal herb:Ocimum gratissimum. International Journal of Cancer, 2007, 121, 884-894.	5.1	63

#	Article	IF	Citations
19	Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition. Molecular Carcinogenesis, 2007, 46, 857-864.	2.7	19
20	Efficacy and Patterns of Failure for Locally Advanced Cancer of the Cervix Treated With Celebrex (Celecoxib) andÂChemoradiotherapy in RTOG 0128. International Journal of Radiation Oncology Biology Physics, 2007, 69, 111-117.	0.8	30
21	The tumour microenvironment as a target for chemoprevention. Nature Reviews Cancer, 2007, 7, 139-147.	28.4	700
22	Action of Celecoxib on Hepatic Metabolic Changes Induced by the Walker-256 Tumour in Rats. Basic and Clinical Pharmacology and Toxicology, 2007, 101, 294-300.	2.5	11
23	COX-2 localization within plasma membrane caveolae-like structures in human lobular intraepithelial neoplasia of the breast. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 1039-1045.	2.8	16
24	Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2. Breast Cancer Research and Treatment, 2008, 111, 209-218.	2.5	36
25	Clinical use and pharmacological properties of selective COX-2 inhibitors. European Journal of Clinical Pharmacology, 2008, 64, 233-252.	1.9	153
26	Chemoprevention of breast cancer. Breast Cancer, 2008, 15, 10-16.	2.9	27
27	Breast cancer chemoprevention. Oncology Reviews, 2008, 2, 223-228.	1.8	6
28	CSâ€706, a novel cyclooxygenaseâ€2 selective inhibitor, prolonged the survival of tumorâ€bearing mice when treated alone or in combination with antiâ€tumor chemotherapeutic agents. International Journal of Cancer, 2008, 122, 1384-1390.	5.1	13
29	Celecoxib concentration predicts decrease in prostaglandin E2concentrations in nipple aspirate fluid from high risk women. BMC Cancer, 2008, 8, 49.	2.6	8
30	Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Healthâ€“AARP Diet and Health Study. Breast Cancer Research, 2008, 10, R38.	5.0	82
31	Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opinion on Investigational Drugs, 2008, 17, 197-208.	4.1	78
32	Modulation of Breast Cancer Risk by Nonsteroidal Anti-inflammatory Drugs. Journal of the National Cancer Institute, 2008, 100, 1420-1423.	6.3	19
33	Combination Chemoprevention of HER2/neu-Induced Breast Cancer Using a Cyclooxygenase-2 Inhibitor and a Retinoid X Receptorâ€“Selective Retinoid. Cancer Prevention Research, 2008, 1, 208-214.	1.5	33
34	Breast Cancer and Use of Nonsteroidal Anti-inflammatory Drugs: A Meta-analysis. Journal of the National Cancer Institute, 2008, 100, 1439-1447.	6.3	193
35	Association Between Cyclooxygenase-2 Expression in Atypical Hyperplasia and Risk of Breast Cancer. Journal of the National Cancer Institute, 2008, 100, 421-427.	6.3	57
36	Nonsteroidal Anti-inflammatory Drugs and Change in Mammographic Density: A Cohort Study Using Pharmacy Records on Over 29,000 Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1088-1095.	2.5	16

#	Article	IF	Citations
37	Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-Â through a PGE2-dependent mechanisms. Carcinogenesis, 2008, 29, 2227-2235.	2.8	153
38	Suppression of Tumor Formation by a Cyclooxygenase-2 Inhibitor and a Peroxisome Proliferator-Activated Receptor Î³ Agonist in an In vivo Mouse Model of Spontaneous Breast Cancer. Clinical Cancer Research, 2008, 14, 4935-4942.	7.0	35
39	Use of Common Medications and Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1564-1595.	2.5	19
40	Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise. Current Pharmaceutical Design, 2008, 14, 2051-2060.	1.9	66
41	Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. European Journal of Cancer Prevention, 2008, 17, 88-96.	1.3	55
42	A Novel Therapeutic Approach to Breast Cancer using a Selective Cyclooxygenase 2 Inhibitor and Adenovirus-mediated Delivery of the Melanoma Differentiation-associated Gene-7 (Ad-mda7). Journal of Breast Cancer, 2008, 11, 49.	1.9	0
43	Lack of Complications in Minor Skin Lesion Excisions in Patients Taking Aspirin or Warfarin Products. American Surgeon, 2008, 74, 354-357.	0.8	18
44	Use of Aspirin, Other Nonsteroidal Anti-inflammatory Drugs, and Acetaminophen and Risk of Breast Cancer Among Premenopausal Women in the Nurses' Health Study II. Archives of Internal Medicine, 2009, 169, 115.	3.8	40
45	Effects of Celecoxib and Ly117018 Combination on Human Breast Cancer Cells in Vitro. Breast Cancer: Basic and Clinical Research, 2009, 3, BCBCR.S2291.	1.1	5
46	Common Polymorphisms in the Prostaglandin Pathway Genes and Their Association with Breast Cancer Susceptibility and Survival. Clinical Cancer Research, 2009, 15, 2181-2191.	7.0	51
47	Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Annals of Oncology, 2009, 20, 615-620.	1.2	61
48	Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers. Journal of Clinical Oncology, 2009, 27, 4986-4993.	1.6	57
49	Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology, 2009, 17, 55-67.	3.9	294
50	Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model. Breast Cancer Research and Treatment, 2009, 117, 517-524.	2.5	17
51	Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Research and Treatment, 2009, 117, 235-242.	2.5	55
52	Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2009, 117, 141-150.	2.5	83
53	Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Research and Treatment, 2009, 116, 501-508.	2.5	38
54	Non-Steroidal Anti-Inflammatory Drugs and Melanoma Risk: Large Dutch Population-Based Caseâ€“Control Study. Journal of Investigative Dermatology, 2009, 129, 2620-2627.	0.7	43

#	Article	IF	Citations
55	Reduced Risk of Bone Metastasis for Patients With Breast Cancer Who Use COX-2 Inhibitors. Clinical Breast Cancer, 2009, 9, 225-230.	2.4	25
56	Breast cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Research, 2009, 11, R56.	5.0	65
57	Ibuprofen Induces Reduction of the Proliferation-Seeking Radiotracer 99m Tc-(V)DMSA Uptake in Severe Epithelial Breast Hyperplasia without Atypia. Molecular Imaging, 2010, 9, 7290.2010.00028.	1.4	2
58	Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studies. Protoplasma, 2010, 246, 109-118.	2.1	1
59	Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes and Control, 2010, 21, 1503-1512.	1.8	43
60	Effect of anaesthetic technique and other perioperative factors on cancer recurrence. British Journal of Anaesthesia, 2010, 105, 106-115.	3.4	514
61	Sulindac and Sulindac Metabolites in Nipple Aspirate Fluid and Effect on Drug Targets in a Phase I Trial. Cancer Prevention Research, 2010, 3, 101-107.	1.5	7
62	Role of traditional and new biomarkers in breast carcinogenesis. Ecancermedicalscience, 2010, 3, 157.	1.1	1
63	Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 177-187.	2.5	97
64	Overexpression of COX-2 in Celecoxib-Resistant Breast Cancer Cell Lines. Journal of Surgical Research, 2010, 163, 235-243.	1.6	15
65	Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention. Journal of the National Cancer Institute, 2010, 102, 14-25.	6.3	658
66	Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Research, 2010, 12, R15.	5.0	27
67	Reduced uptake of the proliferation-seeking radiotracer technetium-99m-labelled pentavalent dimercaptosuccinic acid in a 47-year-old woman with severe breast epithelial hyperplasia taking ibuprofen: a case report. Journal of Medical Case Reports, 2010, 4, 89.	0.8	1
68	Concentration-dependent differing actions of the nonsteroidal anti-inflammatory drug, celecoxib, in distearoyl phosphatidylcholine multilamellar vesicles. Journal of Liposome Research, 2010, 20, 168-177.	3.3	13
69	Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins. Cancer Investigation, 2011, 29, 585-593.	1.3	151
70	Effects of catechin, diclofenac and celecoxib on the proliferation of MCF-7 and LTED MCF-7 cells. Biomedicine and Preventive Nutrition, 2011, 1, 202-206.	0.9	0
71	In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog JCC76 in aromatase inhibitors-insensitive breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2011, 126, 10-18.	2.5	14
72	Preventive therapy for breast cancer: a consensus statement. Lancet Oncology, The, 2011, 12, 496-503.	10.7	196

#	Article	IF	Citations
73	Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft. Veterinary and Comparative Oncology, 2011, 9, 118-130.	1.8	7
74	Design and synthesis of a biotinylated probe of COX-2 inhibitor nimesulide analog JCC76. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5324-5327.	2.2	10
75	Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast, 2011, 20, 66-70.	2.2	47
76	Regular aspirin use and breast cancer risk in US Black Women. Cancer Causes and Control, 2011, 22, 1553-1561.	1.8	30
77	Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer and Metastasis Reviews, 2011, 30, 449-463.	5.9	114
78	Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Molecular and Cellular Biochemistry, 2011, 350, 59-70.	3.1	48
79	Celecoxib steigert die Strahlenempfindlichkeit von sekundÃren Knochentumoren eines nicht-kleinzelligen humanen Lungenkarzinoms durch Anti-Angiogenese in vivo. Strahlentherapie Und Onkologie, 2011, 187, 45-51.	2.0	17
80	Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. Carcinogenesis, 2011, 32, 1441-1449.	2.8	41
81	Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested caseâ€“control studies. British Journal of Cancer, 2011, 105, 452-459.	6.4	40
82	Celecoxib reduces fluidity and decreases metastatic potential of colon cancer cell lines irrespective of COX-2 expression. Bioscience Reports, 2012, 32, 35-44.	2.4	29
83	Prevention of ER-negative breast cancer. European Journal of Cancer Prevention, 2012, 21, 171-181.	1.3	10
84	Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Laboratory Investigation, 2012, 92, 1115-1128.	3.7	115
85	Aspirin and cancer risk: a quantitative review to 2011. Annals of Oncology, 2012, 23, 1403-1415.	1.2	263
86	Angiotensin-converting enzyme inhibitors enhance the effect of cyclooxygenase inhibitors on breast cancer. Journal of Hypertension, 2012, 30, 2432-2439.	0.5	10
87	Preventive Therapy for Breast Cancer. Current Oncology Reports, 2012, 14, 568-573.	4.0	5
88	COX inhibitors Indomethacin and Sulindac derivatives as antiproliferative agents: Synthesis, biological evaluation, and mechanism investigation. European Journal of Medicinal Chemistry, 2012, 56, 17-29.	5.5	32
89	Oleocanthal: A Naturally Occurring Anti-Inflammatory Agent in Virgin Olive Oil. , 0, , .		7
90	Selection of Suitable Reference Genes for Quantitative Real-Time PCR in Apoptosis-Induced MCF-7 Breast Cancer Cells. Molecular Biotechnology, 2012, 50, 121-128.	2.4	29

#	Article	IF	Citations
91	Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Research and Treatment, 2012, 131, 581-587.	2.5	69
92	Chemopreventive effect of diclofenac on mammary carcinogenesis in Sprague-Dawley rats. Biologia (Poland), 2013, 68, 733-737.	1.5	0
93	Tumor-induced Myeloid-derived Suppressor Cells. , 2013, , 473-496.		2
94	Minireview: Obesity and Breast Cancer: A Tale of Inflammation and Dysregulated Metabolism. Molecular Endocrinology, 2013, 27, 715-725.	3.7	70
95	In Vitro Characterization of a Liposomal Formulation of Celecoxib Containing 1,2-Distearoyl-sn-Glycero-3-Phosphocholine, Cholesterol, and Polyethylene Glycol and its Functional Effects Against Colorectal Cancer Cell Lines. Journal of Pharmaceutical Sciences, 2013, 102, 3666-3677.	3.3	9
96	Obesity and breast cancer: role of inflammation and aromatase. Journal of Molecular Endocrinology, 2013, 51, T51-T59.	2.5	75
97	Mammary Carcinoma Cell Derived Cyclooxygenase 2 Suppresses Tumor Immune Surveillanceby Enhancing Intratumoral Immune Checkpoint Activity. Breast Cancer Research, 2013, 15, R75.	5.0	53
98	Candidate cancer-targeting agents identified by expression-profiling arrays. OncoTargets and Therapy, 2013, 6, 447.	2.0	3
99	Preventative therapies for healthy women at high risk of breast cancer. Cancer Management and Research, 2014, 6, 423.	1.9	21
100	Cyclooxygenase-2 and the inflammogenesis of breast cancer. World Journal of Clinical Oncology, 2014, 5, 677.	2.3	143
101	Oleocanthal, a Phenolic Derived from Virgin Olive Oil: A Review of the Beneficial Effects on Inflammatory Disease. International Journal of Molecular Sciences, 2014, 15, 12323-12334.	4.1	114
102	Cyclooxygenaseâ€2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice. BJU International, 2014, 113, E164-77.	2.5	20
103	Are we causing the recurrence-impact of perioperative period on long-term cancer prognosis: Review of current evidence and practice. Journal of Anaesthesiology Clinical Pharmacology, 2014, 30, 153.	0.7	33
104	Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. British Journal of Cancer, 2014, 111, 623-627.	6.4	94
105	COX-2 Promotes Migration and Invasion by the Side Population of Cancer Stem Cell-Like Hepatocellular Carcinoma Cells. Medicine (United States), 2015, 94, e1806.	1.0	40
106	Ibuprofen and Diclofenac Restrict Migration and Proliferation of Human Glioma Cells by Distinct Molecular Mechanisms. PLoS ONE, 2015, 10, e0140613.	2.5	54
107	Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis. Breast Cancer Research and Treatment, 2015, 149, 525-536.	2.5	59
108	Expression of Cyclooxygenase-2 in Squamous Cell Carcinoma and Keratoacanthoma and its Clinical Significance. Cell Biochemistry and Biophysics, 2015, 72, 475-480.	1.8	5

#	Article	IF	Citations
109	Synergistic effect between celecoxib and luteolin is dependent on estrogen receptor in human breast cancer cells. Tumor Biology, 2015, 36, 6349-6359.	1.8	26
110	Update on breast cancer risk prediction and prevention. Current Opinion in Obstetrics and Gynecology, 2015, 27, 92-97.	2.0	27
111	Aspirin Use and Risk of Breast Cancer: Systematic Review and Meta-analysis of Observational Studies. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1645-1655.	2.5	45
112	COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/WNT Axis. Stem Cells, 2016, 34, 2290-2305.	3.2	95
113	Immune Suppressive Myeloid-Derived Suppressor Cells in Cancer. , 2016, , 512-525.		3
114	Use of acetaminophen in relation to the occurrence of cancer: a review of epidemiologic studies. Cancer Causes and Control, 2016, 27, 1411-1418.	1.8	9
115	Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study. BMC Cancer, 2016, 16, 660.	2.6	26
116	COX-2 inhibitors: a novel strategy in the management of breast cancer. Drug Discovery Today, 2016, 21, 598-615.	6.4	76
117	Tolerance and immune suppression in the tumor microenvironment. Cellular Immunology, 2016, 299, 23-29.	3.0	41
118	Wnt Signaling as a Therapeutic Target in Cancer and Metastasis. , 2017, , 375-394.		3
119	Interaction of a common painkiller piroxicam and copper-piroxicam with chromatin causes structural alterations accompanied by modulation at the epigenomic/genomic level. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2048-2059.	2.4	8
120	Cyclooxygenase-2 in glioblastoma multiforme. Drug Discovery Today, 2017, 22, 148-156.	6.4	103
121	Tumor Cell Invasion Induced by Radiation in Balb/C Mouse is Prevented by the Cox-2 Inhibitor NS-398. Radiation Research, 2017, 188, 685-694.	1.5	5
122	A Methodology for Cancer Therapeutics by Systems Pharmacology-Based Analysis: A Case Study on Breast Cancer-Related Traditional Chinese Medicines. PLoS ONE, 2017, 12, e0169363.	2.5	17
123	Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity. Breast Cancer: Targets and Therapy, 2017, Volume 9, 85-93.	1.8	20
124	COX-2 induces oncogenic micro RNA miR655 in human breast cancer. Scientific Reports, 2018, 8, 327.	3.3	51
125	Mechanisms of Phytonutrient Modulation of Cyclooxygenase-2 (COX-2) and Inflammation Related to Cancer. Nutrition and Cancer, 2018, 70, 350-375.	2.0	135
126	Familial Mediterranean Fever and Incidence of Cancer. Arthritis and Rheumatology, 2018, 70, 127-133.	5.6	27

#	Article	IF	Citations
127	Celecoxib in breast cancer prevention and therapy. Cancer Management and Research, 2018, Volume 10, 4653-4667.	1.9	53
128	Combined Modulation of Tumor Metabolism by Metformin and Diclofenac in Glioma. International Journal of Molecular Sciences, 2018, 19, 2586.	4.1	23
129	Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer. Cancer and Metastasis Reviews, 2018, 37, 369-384.	5.9	48
130	EP4 as a Therapeutic Target for Aggressive Human Breast Cancer. International Journal of Molecular Sciences, 2018, 19, 1019.	4.1	59
131	Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer, 2018, 18, 288.	2.6	118
132	EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer. BMC Cancer, 2018, 18, 431.	2.6	15
133	Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. Journal of Translational Medicine, 2018, 16, 8.	4.4	204
134	EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells . OncoTargets and Therapy, 2019, Volume 12, 6053-6068.	2.0	12
135	Human cytomegalovirus infection is correlated with enhanced cyclooxygenase-2 and 5-lipoxygenase protein expression in breast cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2083-2095.	2.5	24
136	Prostaglandin E2 promotes embryonic vascular development and maturation in zebrafish. Biology Open, 2019, 8, .	1.2	11
137	Nonaspirin NSAIDs and contralateral breast cancer risk. International Journal of Cancer, 2019, 144, 1243-1250.	5.1	6
138	Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment. Journal of Cellular Physiology, 2019, 234, 5613-5627.	4.1	64
139	Aspirin might reduce the incidence of breast cancer. Medicine (United States), 2020, 99, e21917.	1.0	16
140	An Industrial and Sustainable Platform for the Production of Bioactive Micronized Powders and Extracts Enriched in Polyphenols From Olea europaea L. and Vitis vinifera L. Wastes. Frontiers in Nutrition, 2020, 7, 120.	3.7	28
141	S-nitrosylated and non-nitrosylated COX2 have differential expression and distinct subcellular localization in normal and breast cancer tissue. Npj Breast Cancer, 2020, 6, 62.	5.2	7
142	Prognostic Significance of Prostaglandin-Endoperoxide Synthase-2 Expressions in Human Breast Carcinoma: A Multiomic Approach. Cancer Informatics, 2020, 19, 117693512096969.	1.9	4
143	Iron: An Essential Element of Cancer Metabolism. Cells, 2020, 9, 2591.	4.1	56
144	EP3 Is an Independent Prognostic Marker Only for Unifocal Breast Cancer Cases. International Journal of Molecular Sciences, 2020, 21, 4418.	4.1	3

#	Article	IF	Citations
145	Metformin as Potential Therapy for High-Grade Glioma. Cancers, 2020, 12, 210.	3.7	52
146	Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019. Clinical Breast Cancer, 2021, 21, 552-565.	2.4	36
147	A systematic assessment of the epidemiologic literature regarding an association between acetaminophen exposure and cancer. Regulatory Toxicology and Pharmacology, 2021, 127, 105043.	2.7	3
148	Can anesthetic effects and pain treatment influence the long-term prognosis of early-stage lymph node-negative breast cancer after breast-conserving surgery?. Annals of Translational Medicine, 2021, 9, 1467-1467.	1.7	6
150	Anticancer molecular mechanisms of oleocanthal. Phytotherapy Research, 2020, 34, 2820-2834.	5.8	15
151	Immune Modulation and Cancer Resistance. , 2008, , 285-307.		1
153	Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. Oncotarget, 2014, 5, 1458-1474.	1.8	52
154	Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. Journal of Experimental Pharmacology, 2012, 4, 91.	3.2	33
155	Drug Repurposing in the Development of Anticancer Agents. Current Medicinal Chemistry, 2019, 26, 5410-5427.	2.4	18
156	Oleocanthal, a Natural anti-Inflammatory Compound in Extra Virgin Olive Oil. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2010, 9, 94-100.	1.1	2
157	Vitamin D3 Treatment Influences PGE2 and TGFÎ² in Normal and Increased Breast Cancer Risk Women. Anticancer Research, 2016, 36, 5347-5354.	1.1	4
158	Etoricoxib in the Prevention of Rat Mammary Carcinogenesis. Acta Veterinaria Brno, 2007, 76, 613-618.	0.5	3
159	The Role of the LY294002 - A Non-Selective Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) Pathway- in Cell Survival and Proliferation in Cell Line SCC-25. Asian Pacific Journal of Cancer Prevention, 2019, 20, 3377-3383.	1.2	15
160	Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World Journal of Gastroenterology, 2008, 14, 4535.	3.3	17
161	Chemoprevention of breast cancer by cyclooxygenase and lipoxygenase inhibitors. World Academy of Sciences Journal, 0, , .	0.6	3
162	Scintimammography - Molecular Imaging: Value and New Perspectives with 99mTc(V)-DMSA. , 0, , .		1
163	The Role of Celecoxib as a Cox-2 Inhibitor Increasing the Radiosensitivity of Tumor Tissue. British Journal of Medicine and Medical Research, 2015, 8, 123-139.	0.2	3
167	Pharmacologic Interventions with NSAIDs. , 2013, , 257-303.		0

#	Article	IF	Citations
168	Therapeutic Strategies, the Concept of â€œNormalizationâ€•and the Role of VEGF Inhibition. , 2016, , 51-60.		0
169	Chemoprevention of Breast Cancer. , 2016, , 593-600.		0
170	Chemoprevention and Angiogenesis. , 2017, , 123-144.		0
171	The Role of Chemoprevention in theÂPrevention of Breast Cancer. , 2018, , 129-145.		0
172	Clinical trials on combination of repurposed drugs and anticancer therapies. , 2020, , 395-437.		0
174	Association of Promoter Polymorphisms -765G/C and -1195A/G with Migraine. Iranian Journal of Public Health, 2016, 45, 1625-1635.	0.5	7
175	Selective EP2 and Cox-2 inhibition suppresses cell migration by reversing epithelial-to-mesenchymal transition and Cox-2 overexpression and E-cadherin downregulation are implicated in neck metastasis of hypopharyngeal cancer. American Journal of Translational Research (discontinued), 2020, 12, 1096-1113.	0.0	8
177	Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study. European Journal of Clinical Nutrition, 2022, 76, 1343-1346.	2.9	3
178	Drug repurposingâ€”an emerging strategy in cancer therapeutics. Naunyn-Schmiedeberg's Archives of Pharmacology, 0, , .	3.0	12
179	Antiproliferative activity of new derivatives of pyrazino[1,2â€•a]benzimidazole: Integrated cellâ€based assay and computational studies with divalent magnesium, iron, and copper ions. Journal of Biochemical and Molecular Toxicology, 0, , .	3.0	0
180	Chalcones: Promising therapeutic agents targeting key players and signaling pathways regulating the hallmarks of cancer. Chemico-Biological Interactions, 2023, 369, 110297.	4.0	28
181	Cyclooxygenaseâ€2 as a therapeutic target against human breast cancer: A comprehensive review. WIREs Mechanisms of Disease, 2023, 15, .	3.3	5
182	Human cytomegalovirus infection enhances 5â€‘lipoxygenase and cycloxygenaseâ€‘2 expression in colorectal cancer. International Journal of Oncology, 2023, 63, .	3.3	0